SELLAS Life Sciences Group, Inc. is a late-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The Companyâs lead product candidate, galinpepimut-S, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets a broad spectrum of hematologic cancers and solid tumor indications. Galinpepimut-S is poised to enter pivotal Phase 3 clinical trials, pending funding availability, in patients with AML and Mesothelioma.
Source
